The entry of non-human-derived antibodies into the human body can cause serious rejection of the organism, which in turn affects the safety and therapeutic efficacy of the antibody in clinical applications. Humanized antibodies are genetically modified so that murine antibodies have a structure similar to that of human antibodies, thus evading recognition by the immune system. Antibody humanization has undergone technological evolution from chimeric antibodies to CDR grafting and SDR grafting, aiming to overcome the immunogenicity of traditional murine antibodies while maintaining high affinity and high specificity binding ability, and has extremely promising applications in tumor therapy and other fields.
Based on the deep learning algorithm of artificial intelligence, DetaiBio’s humanization service can obtain antibody sequences with high degree of humanization and low mutation energy by constructing antibody structure model, CDR grafting and back mutation, identifying key amino acids and humanization operation. During the humanization process, both heavy and light chains are involved in the optimization, and the obtained heavy and light chains do not need to be combined for subsequent expression; antibodies from multiple species can be humanized to ensure that the degree of humanization of the V region of the delivered sequence is greater than 85%, and the overall degree of humanization of the FV region is greater than 90%, ensuring that the affinity of the delivered humanized antibody is comparable to that of the initial antibody.
Heavy and light chains
Affinity of the humanized
antibody is comparable
to the initial antibody
can be huamnized
|Design of Humanized Antibody||3 weeks|
|Candidates Activity Assay||2 weeks|
|Humanized Antibody Expression & Purification||1 week|
The humanized antibodies (6A, 7A, 8A, 2B) were found to have comparable affinity to the initial mouse-derived antibody (WT) by ELISA and FACS activity assay.